Takeda UK announced today that all sales teams and support resource will be integrated into the company effective 1 st June 2016.
The field sales teams have been operated and managed by Ashfield Healthcare since 2004. This announcement impacts over 70 team members of the Oncology Key Account Manager (KAM) team, Inflammatory Bowel Disease (IBD) KAM team and the entire General Medicine Regional Account Director (RAD) and Customer Account Specialist (CAS) teams.
These team members will transition to become Takeda employees from 1st June, 2016 following the conclusion of a consultation and transition process in line with legislative requirements.
This move will nearly double the number of Takeda employees in the UK and is part of an ambitious growth strategy to become an agile, specialty care provider focused on specific opportunities in Oncology, IBD and Diabetes.
Adam Zaeske, Managing Director, Takeda UK & Ireland said: “Takeda and Ashfield Healthcare were pioneers when the RAD/KAM model was conceived in 2004. The partnership has been a tremendous success and is still recognised with many major companies adopting a similar approach.”
“Today Takeda is at the cusp of a significant growth phase with specific opportunities in Oncology, IBD and Diabetes. We have made the strategic decision to integrate our sales teams as we recognise the critical role they play in growing our business and continuing to build a strong organisation.”
“This is an incredibly exciting time for Takeda as we transform our business as an agile, specialty care provider. This announcement is about forging one integrated team and is the latest step in that journey.”
“I sincerely thank our partners at Ashfield Healthcare for their hard work and support over the years. This announcement is a validation of Ashfield’s ability to help build healthcare companies and propel them forward through expertise and ingenuity. Takeda UK is strong today in large measure because of our partnership with Ashfield Healthcare.”
Source: Takeda
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
